Evero DCB
AssetAlso Advance Evero 18
Delivers everolimus locally to inhibit mTOR and vascular smooth muscle proliferation, limiting restenosis after angioplasty.
- Stage
- Human trials
- Modality
- Device
- Target
- mTOR signalling
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Peripheral arterial disease
Human trials, Recruiting, NCT07144150, clinicaltrials.gov, 16 Oct 2026
Peripheral vascular disease
Human trials, Recruiting, NCT07144150, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors2
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.